NVS - Novartis' Rare Blood Disorder Therapy Scores FDA Approval | Benzinga
The FDA approved Novartis AG's (NYSE: NVS) Fabhalta (iptacopan) as the first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
PNH is an acquired (not inherited) disorder that leads to premature death and impaired production of blood cells. It is estimated that approximately 10-20 people per million worldwide live with PNH.
Fabhalta is a Factor B inhibitor that acts ...